• WKN: STRA55
  • ISIN: DE000STRA555
  • Land: Deutschland

Analyst Coverage

Institute Analysts Phone
Berenberg Bank Scott Bardo +44 20 32077869
Deutsche Bank Jan Koch +49 69 91047428
Kepler Cheuvreux Oliver Reinberg +49 69 75696140
Landesbank Baden-Württemberg Volker Stoll +49 711 12770568
Metzler Capital Markets Alexander Neuberger +49 69 21044366
ODDO BHF Oliver Metzger +49 69 7183045
SRH AlsterResearch Dr. Oliver Wojahn +49 40 30929358
Warburg Research Michael Heider +49 40 309537280

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021